Spinal muscular atrophy (SMA) is a severe neurological disease for which there is presently no cure, although current therapies can alleviate symptoms. In the search for better treatment options, ...
Spinal muscular atrophy (SMA) is a genetic disease that affects the nervous system and, mostly, the muscles it controls. It weakens muscles and can lead to problems breathing, eating, and walking. SMA ...
Add Yahoo as a preferred source to see more of our stories on Google. Jun. 14—HARLINGEN — Kristen Resendez beams with happiness knowing other parents will not have to go through what she and her son ...
Leptin merely correlated with body mass index, the study found. A new report on patients with types II and III spinal muscular atrophy (SMA) has found that levels of the peptide hormone leptin are ...
Qualitative interviews conducted with caregivers of children with spinal muscular atrophy (SMA) found that the symptoms with the greatest effect on disease burden were not always the most prevalent ...
MIAMI - Celine Domalski was busy riding her unicorn at her Miami Beach condo as she readied to walk in a very important fashion show. "I'm doing a fashion show," Celine told Lisa Petrillo. "Are you ...
– Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and safety as the currently available oral solution – – New tablet formulation may provide greater freedom ...
The MarketWatch News Department was not involved in the creation of this content. -- Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients ...
Spinal muscular atrophy is a disease that is usually seen in babies and children. It makes their muscles weak and hard to move. It's a rare illness that is passed down in families. SMA isn’t the only ...
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results